Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials

BACKGROUND: The effects of liraglutide treatment on the left ventricular systolic and diastolic function remain unclear. METHODS: This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. All relevant randomized, placebo-controlled trials (RCTs) were identified by searching PubMed, EMBASE, Cochrane Library, and ISI Web of Science from the establishment to January 2021 without language limitations. The weighted mean difference (WMD) with 95% confidence intervals (CIs) was calculated. RESULTS: Ten placebo-controlled RCTs involving a total of 732 cases were included in the meta-analysis. Compared with the placebo group, liraglutide therapy showed no beneficial effect on the left ventricular ejection fraction (LVEF) at the end of the study (WMD: 2.120, 95% CI: −0.688 to 4.929, P=0.139) and ΔLVEF during the trial period (WMD: −0.651, 95% CI: −1.649 to 0.348, P=0.202). Similarly, no statistical differences were noted in diastolic function parameters between the two groups, including the value early diastolic filling velocity (E)/the mitral annular early diastolic velocity (e′) (WMD: −0.763, 95% CI: −2.157 to 0.630, P=0.283), Δe′ (WMD: −0.069, 95% CI: −0.481 to 0.343, P=0.742), and ΔE/e′ (WMD: −0.683, 95% CI: −1.663 to 0.298, P=0.172). CONCLUSIONS: Liraglutide treatment did not improve the left ventricular systolic and diastolic function. Given the study's limitations, further investigation may be warranted.